This announcement contains inside information for the purposes of the UK Market Abuse Regulations ('UK MAR'). Upon publication of this announcement, this inside information (as defined in UK MAR) is now considered to be in the public domain. The person responsible for arranging the release of this announcement on behalf of the Company is tim mccarthy, Chief Executive Officer.

27 March 2026

ImmuPharma PLC

("ImmuPharma" or the "Company")

P140 Program Update

- patent progress |new supporting data | scientific publication in preparation -

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to provide an update on its auto-immune technology platform program, P140.

The Company has received a first Combined Search and Examination Report ("CSER") in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application. ImmuPharma intends, in due course, to build on this filing through a Patent Cooperation Treaty ("PCT") application, with a view to seeking protection in key commercial territories. (See notes).

In parallel, ImmuPharma has completed a new study, intended to provide further supporting data for the patent application. The study was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset. The Company is pleased to report that the results were positive and supportive of the patent application.

The scientific team, led by Dr Sébastien Goudreau, CSO, and Dr Laura Mauran, Head of R&D, is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community.

P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value‑enhancing licensing deal in 2026.

Dr Sébastien Goudreau, Chief Scientific Officer of ImmuPharma PLC, said:

"The receipt of the first Combined Search and Examination Report for our UK P140 patent application, together with the new supporting study results, represents an important step in strengthening the scientific and intellectual property foundation of the program. In parallel, the scientific manuscript now in preparation will help the broader scientific community to understand the unique mechanism of P140 as a precision therapy for patients with Type M immune disorder. This work reinforces our confidence in P140's potential to become a first‑in‑class, disease‑modifying approach across multiple autoimmune diseases."

ImmuPharma will provide further updates on the P140 program as appropriate.

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

The Patent Cooperation Treaty ("PCT")

PCT is an international agreement that allows the applicant to file a single "international" patent application to keep options open for patent protection in many countries at once, rather than filing separately in each country on day one.